<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059215</url>
  </required_header>
  <id_info>
    <org_study_id>7145</org_study_id>
    <secondary_id>H7T-MC-TAAH</secondary_id>
    <nct_id>NCT00059215</nct_id>
  </id_info>
  <brief_title>A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 Compared With Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as
      prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also
      referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in
      the heart using a catheter (a long thin tube) that has a small balloon on the end. In many
      cases, patients who have this procedure receive a stent, a small wire spring that helps keep
      the vessel open.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events</measure>
    <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding.
A major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.
A minor bleed was defined as a clinically overt hemorrhage with a hemoglobin decrease &gt;=3 g/dL and &lt;= 5 g/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of participants with any of the following: death, nonfatal myocardial infarction, stroke, total or subtotal occlusion of the target vessel, urgent target vessel revascularization, recurrent ischemia requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-Coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</measure>
    <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding.
A major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-CABG TIMI Major or Minor Bleeding Plus MACE</measure>
    <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding or MACE.
Major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.
Minor bleed was defined as a clinically overt hemorrhage with a hemoglobin decrease &gt;=3 g/dL and &lt;= 5 g/dL.
MACE is any of the following:death, nonfatal myocardial infarction, stroke, total or subtotal occlusion of the target vessel, urgent target vessel revascularization, recurrent ischemia requiring hospitalization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">905</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Prasugrel (CS-747) 40 mg LD/7.5 mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel (CS-747) 60 mg LD/10 mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel (CS-747) 60 mg LD/15 mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel (CS-747)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Prasugrel (CS-747) 40 mg LD/7.5 mg MD</arm_group_label>
    <arm_group_label>Prasugrel (CS-747) 60 mg LD/10 mg MD</arm_group_label>
    <arm_group_label>Prasugrel (CS-747) 60 mg LD/15 mg MD</arm_group_label>
    <other_name>Prasugrel</other_name>
    <other_name>LY640315</other_name>
    <other_name>Effient</other_name>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be candidates for elective or urgent PCI with intended coronary
             stenting.

          -  Men or non-pregnant women (that is, postmenopausal women, women who are surgically
             sterile, or women of childbearing potential who have a negative urine or serum
             pregnancy test) who are greater than or equal to 18 and less than or equal to 75 years
             of age.

        Exclusion Criteria:

          -  Patients must not have planned PCI procedure as initial treatment for an acute
             ST-elevation acute myocardial infarction (STEMI)

          -  Patients must not be receiving or will receive oral anticoagulation therapy that
             cannot be safely discontinued for the duration of the study

          -  Patients must not have cardiogenic shock or severe congestive heart failure

          -  Patients must not have active internal bleeding or history of bleeding diathesis

          -  Patients must not have prior history of hemorrhagic cerebrovascular accident (CVA) or
             nonhemorrhagic CVA within 2 years of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4599) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2003</study_first_submitted>
  <study_first_submitted_qc>April 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2003</study_first_posted>
  <results_first_submitted>April 19, 2010</results_first_submitted>
  <results_first_submitted_qc>April 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2010</results_first_posted>
  <last_update_submitted>May 21, 2010</last_update_submitted>
  <last_update_submitted_qc>May 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel (CS-747) 40-mg LD/7.5 mg MD</title>
          <description>Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="P2">
          <title>Prasugrel (CS-747) 60-mg LD/10-mg MD</title>
          <description>Prasugrel (CS-747) 60-mg oral loading dose (LD) at time of PCI followed by 10-mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="P3">
          <title>Prasugrel (CS-747) 60-mg LD/15-mg MD</title>
          <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="P4">
          <title>Clopidogrel</title>
          <description>Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="251"/>
                <participants group_id="P4" count="254"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187">One subject discontinued before receiving treatment and is not included in the evaluable set.</participants>
                <participants group_id="P2" count="186"/>
                <participants group_id="P3" count="236"/>
                <participants group_id="P4" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol entry criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel (CS-747) 40 mg LD/7.5 mg MD</title>
          <description>Prasugrel (CS-747) 40-mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5-mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="B2">
          <title>Prasugrel (CS-747) 60 mg LD/10 mg MD</title>
          <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="B3">
          <title>Prasugrel (CS-747) 60-mg LD/15-mg MD</title>
          <description>Prasugrel (CS-747) 60-mg oral loading dose (LD) at time of PCI followed by 15-mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="B4">
          <title>Clopidogrel</title>
          <description>Clopidogrel 300-mg oral LD at time of PCI followed by an oral 75-mg MD; taken once a day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="199"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="251"/>
            <count group_id="B4" value="254"/>
            <count group_id="B5" value="904"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;18 and &lt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="195"/>
                    <measurement group_id="B5" value="661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="8.72"/>
                    <measurement group_id="B2" value="58.7" spread="9.15"/>
                    <measurement group_id="B3" value="59.4" spread="8.97"/>
                    <measurement group_id="B4" value="58.4" spread="9.17"/>
                    <measurement group_id="B5" value="59.2" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="198"/>
                    <measurement group_id="B4" value="195"/>
                    <measurement group_id="B5" value="696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="226"/>
                    <measurement group_id="B4" value="238"/>
                    <measurement group_id="B5" value="824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East/Southeast Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="208"/>
                    <measurement group_id="B5" value="723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events</title>
        <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding.
A major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.
A minor bleed was defined as a clinically overt hemorrhage with a hemoglobin decrease &gt;=3 g/dL and &lt;= 5 g/dL.</description>
        <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
        <population>Patients who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel (CS-747) 40-mg LD/7.5-mg MD</title>
            <description>Prasugrel (CS-747) 40-mg oral loading dose (LD) at time of PCI followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel (CS-747) 60-mg LD/10-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel (CS-747) 60-mg LD/15-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel</title>
            <description>Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel (CS-747) Combined</title>
            <description>All evaluable patients in the 3 prasugrel (CS-747) treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events</title>
          <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding.
A major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.
A minor bleed was defined as a clinically overt hemorrhage with a hemoglobin decrease &gt;=3 g/dL and &lt;= 5 g/dL.</description>
          <population>Patients who received at least one dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="251"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.933</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.590</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Adverse Cardiovascular Events (MACE)</title>
        <description>Number of participants with any of the following: death, nonfatal myocardial infarction, stroke, total or subtotal occlusion of the target vessel, urgent target vessel revascularization, recurrent ischemia requiring hospitalization.</description>
        <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel (CS-747) 40-mg LD/7.5-mg MD</title>
            <description>Prasugrel (CS-747) 40-mg oral loading dose (LD) at time of PCI followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel (CS-747) 60-mg LD/10-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel (CS-747) 60-mg LD/15-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel</title>
            <description>Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel (CS-747) Combined</title>
            <description>All evaluable patients in the 3 prasugrel (CS-747) treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Cardiovascular Events (MACE)</title>
          <description>Number of participants with any of the following: death, nonfatal myocardial infarction, stroke, total or subtotal occlusion of the target vessel, urgent target vessel revascularization, recurrent ischemia requiring hospitalization.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="251"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.260</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-Coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</title>
        <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding.
A major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.</description>
        <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel (CS-747) 40-mg LD/7.5-mg MD</title>
            <description>Prasugrel (CS-747) 40-mg oral loading dose (LD) at time of PCI followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel (CS-747) 60-mg LD/10-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel (CS-747) 60-mg LD/15-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel</title>
            <description>Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel (CS-747) Combined</title>
            <description>All evaluable patients in the 3 prasugrel (CS-747) treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-Coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</title>
          <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding.
A major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="251"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.544</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-CABG TIMI Major or Minor Bleeding Plus MACE</title>
        <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding or MACE.
Major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.
Minor bleed was defined as a clinically overt hemorrhage with a hemoglobin decrease &gt;=3 g/dL and &lt;= 5 g/dL.
MACE is any of the following:death, nonfatal myocardial infarction, stroke, total or subtotal occlusion of the target vessel, urgent target vessel revascularization, recurrent ischemia requiring hospitalization</description>
        <time_frame>randomization though 30 days after percutaneous coronary intervention (PCI)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel (CS-747) 40-mg LD/7.5-mg MD</title>
            <description>Prasugrel (CS-747) 40-mg oral loading dose (LD) at time of PCI followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel (CS-747) 60-mg LD/10-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O3">
            <title>Prasugrel (CS-747) 60-mg LD/15-mg MD</title>
            <description>Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days</description>
          </group>
          <group group_id="O4">
            <title>Clopidogrel</title>
            <description>Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.</description>
          </group>
          <group group_id="O5">
            <title>Prasugrel (CS-747) Combined</title>
            <description>All evaluable patients in the 3 prasugrel (CS-747) treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-CABG TIMI Major or Minor Bleeding Plus MACE</title>
          <description>Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding or MACE.
Major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a &gt;5 g/dL decrease in hemoglobin.
Minor bleed was defined as a clinically overt hemorrhage with a hemoglobin decrease &gt;=3 g/dL and &lt;= 5 g/dL.
MACE is any of the following:death, nonfatal myocardial infarction, stroke, total or subtotal occlusion of the target vessel, urgent target vessel revascularization, recurrent ischemia requiring hospitalization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="251"/>
                <count group_id="O4" value="254"/>
                <count group_id="O5" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel (CS-747) 40-mg LD/7.5 mg MD</title>
          <description>Prasugrel (CS-747) 40-mg oral loading dose (LD) at time of PCI followed by 7.5-mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="E2">
          <title>Prasugrel (CS-747) 60-mg LD/10 mg MD</title>
          <description>Prasugrel (CS-747) 60-mg oral loading dose (LD) at time of PCI followed by 10-mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="E3">
          <title>Prasugrel (CS-747) 60-mg LD/15-mg MD</title>
          <description>Prasugrel (CS-747) 60-mg oral loading dose (LD) at time of PCI followed by 15-mg oral maintenance dose (MD), once daily, for 29-34 days</description>
        </group>
        <group group_id="E4">
          <title>Clopidogrel</title>
          <description>Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="251"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="251"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood in stool</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Cardiac output decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioneurotic oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial haemorrhage nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypotension nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Ischaemia nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="192" subjects_at_risk="251"/>
                <counts group_id="E4" subjects_affected="195" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="251"/>
                <counts group_id="E4" events="25" subjects_affected="23" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Bradycardia nos</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="251"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="251"/>
                <counts group_id="E4" events="26" subjects_affected="24" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site discharge</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="251"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Catheter site ecchymosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="199"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="200"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="251"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="199"/>
                <counts group_id="E2" events="36" subjects_affected="35" subjects_at_risk="200"/>
                <counts group_id="E3" events="39" subjects_affected="37" subjects_at_risk="251"/>
                <counts group_id="E4" events="31" subjects_affected="30" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="199"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="251"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="251"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="200"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="251"/>
                <counts group_id="E4" events="29" subjects_affected="28" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="251"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="251"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="199"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="251"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="251"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="200"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="251"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="200"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="251"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension nos</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="251"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="254"/>
              </event>
              <event>
                <sub_title>Hypotension nos</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="254"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

